ZEE Business
ZEE BUSINESS
हिंदी में पढ़ें  हिंदी में पढ़ें
Live TV
Live TV
  • Home
  • Personal Finance
  • Adani Saga
  • Markets
    • Stocks
    • Global Markets
    • IPO
    • Companies
    • Currency
    • Commodities
  • My Money
  • Calculators
    • Income Tax Calculator
    • Home Loan/EMI Calculator
    • Mutual Fund Returns Calculator
    • Personal Loan Calculator
    • Car Loan Calculator
    • SIP calculator
    • Lumpsum Calculator
    • SWP Calculator
  • Videos
    • M Se Market
    • Jeb Zindagi Zaroorat
    • Light Camera Stocks
    • Tech Takes
    • Big Bulls Ka Nishana
    • Paisa Wasool
    • Commodity Ke MrityunjayMantra
    • The Right Property Show
  • Economy & Infra
    • Policy & Initiatives
    • Agriculture
    • Telecom
    • Aviation
    • Railways
    • Retail
    • Roadways
    • World Economy
  • Exclusive
    • Wealth Guide
    • Interviews
  • Auto
    • Cars
    • Bikes
    • Electric Vehicle
    • Commercial Vehicles
  • Tech
    • Mobiles
    • Gadgets
    • Reviews
    • Tips and Tricks
    • Apps
  • Real Estate
    • Home Buyers
    • Builders
  • Axis MF
  • Trending
    • Entertainment
    • Politics
    • Lifestyle
    • Travel
    • Sports
    • Viral
    • Education
    • Jobs
Read in App
Business News » Markets News

Laurus Labs share price: Sharekhan retains Buy recommendation with a revised price target of Rs 450

Sharekhan had an interaction with Laurus Labs management and their commentary was positive, pointing towards a robust growth outlook. Laurus’ formulations business is on a strong growth footing, backed by a higher quantum of launches in the US as well as opportunities from in-licensing of products, in addition to traction in anti-retrovirals (ARVs).

  • Twitter
  • Facebook
  • Linkedin
  • whatapp
  • View in App
Laurus Labs share price: Sharekhan retains Buy recommendation with a revised price target of Rs 450
Laurus Labs API segment is also well set to clock strong growth backed by the company’s increasing focus to diversify into new therapy areas - anti-diabetes and cardiology: Image taken from companies website

Sharekhan had an interaction with Laurus Labs management and their commentary was positive, pointing towards a robust growth outlook. Laurus’ formulations business is on a strong growth footing, backed by a higher quantum of launches in the US as well as opportunities from in-licensing of products, in addition to traction in anti-retrovirals (ARVs). Sharekhan retains Buy recommendation on Laurus Labs with a revised price target of Rs 450. Laurus Labs share price closed yesterday at Rs 365, up Rs 18 or 5.3%.

Laurus Labs API segment is also well set to clock strong growth backed by the company’s increasing focus to diversify into new therapy areas - anti-diabetes and cardiology along with an eye to gain a foothold in the second line treatment for ARVs. Laurus Labs’ synthesis business is also expected to grow in double digits backed by client additions and increasing commercialization of products.

See Zee Business Live TV Streaming Below:

Laurus Labs has incorporated a dedicated subsidiary to house the synthesis business, which would facilitate improved focus on growth. To cater to rising demand, Laurus Labs is expanding capacities, in two stages - the first leg of debottlenecking is expected to be completed by April 2021 and would add up around 15% of the capacities, while the second leg of expansion would be done by December 2021. Post this company would almost double its formulations capacities.

Further, the recent foray in the biologics space through Laurus Bio augurs well and the benefits would accrue over the medium term. Considering a long term horizon of 3-5 years, Laurus has charted out its growth trajectory encompassing all segments and the management aspires to grow its revenues beyond $1bn in size.

A strong management bandwidth, investments towards upskilling manpower and building capabilities and capacities would enable it to achieve the goal. The above positives point to a strong growth trajectory for Laurus Labs going ahead. Sharekhan expects Laurus Labs to report sales and adjusted profit CAGR of 32% and 73%, respectively, over FY2020-FY2023.

Laurus Labs Key Risks:

Deferral in product approvals or any negative outcome of facility inspection by regulators can affect earnings prospects

 

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.

TAGS:
Laurus Labs
Reported By: ZeeBiz WebTeam
Written By: Rahul Kamdar
Edited By: Harish Dugh
Updated: Thu, Mar 11, 2021
09:30 am
Mumbai, ZeeBiz WebDesk
RELATED NEWS
Sharp spike in Akash Bhanshali, LIC-owned stock after robust Q3 results announcement Sharp spike in Akash Bhanshali, LIC-owned stock after robust Q3 results announcement
Traders Diary on 20 stocks: Buy, Sell or Hold strategy on Tata Motors, Infosys, Sun Pharma, Laurus Labs, others Traders Diary on 20 stocks: Buy, Sell or Hold strategy on Tata Motors, Infosys, Sun Pharma, Laurus Labs, others
Muhurat Picks 2022: Brokerages choose these 5 bets for bumper returns between 22-32% upside on long-term basis – Details Muhurat Picks 2022: Brokerages choose these 5 bets for bumper returns between 22-32% upside on long-term basis – Details
Technical Check: This pharma stock records a bullish double bottom reversal pattern; 20% upside possible in 6-9 months Technical Check: This pharma stock records a bullish double bottom reversal pattern; 20% upside possible in 6-9 months
Laurus Labs shares spurt 17% from day’s low on the back of heavy volumes, positive outlook Laurus Labs shares spurt 17% from day’s low on the back of heavy volumes, positive outlook

LATEST NEWS

Rising Covid cases may lead to surge in hospitalisation, ICU stays: Doctors

Chaitra Navratri Day 7 2023: Know shubh muhurat, puja rituals, and auspicious colour - Details here

Cipla, Lupin, Glenmark other pharma stocks stuck in narrow range after NPPA revises price of 25 drug formulations

Vedanta Dividend 2023: Board meeting today to consider dividend payout: record date fixed

PM Kisan 14th Installment date: When will beneficiaries receive next installment - Check status, list online

PAN-Aadhaar link Deadline 2023: What happens if you fail to link them before March 31?

COVID-19 active cases have increased to 10,981 in India — these are the latest symptoms

NPPA fixes retail prices of 25 drug formulations

Samsung Galaxy Book3 Pro Review: Perfect companion for Samsung smartphone users

Mamaearth's parent puts IPO on hold amid weak market conditions

  • India News
  • World News
  • Companies News
  • Market News
  • Personal Finance News
  • Technology News
  • Automobile News
  • Small Business News
  • Income Tax Calculator
  • Live TV
  • Videos
  • Photos
  • Author
  • Rss Feed
  • Advertise with us
  • Privacy Policy
  • Legal Disclaimer

Latest Trending Updates

  • EPFO
  • Budget 2020
  • Income Tax Return
  • Auto Expo 2020
  • Home Loan
  • Business News

Trending Topics

  • Income Tax
  • income Tax Calculator
  • 7th Pay Commission
  • Reserve Bank of India
  • GST
  • Latest Business News

Follow us on

zeebiz
zeebiz

Partner Sites

  • Zee News
  • Hindi News
  • Marathi News
  • Bengali News
  • Tamil News
  • Malayalam News
  • Gujarati News
  • Telugu News
  • Kannada News
  • DNA
  • WION
© 2023. Indiadotcom Digital Private Limited. All Rights Reserved.
LIVE TV